NSGC 2026 has ended. This guide stays up as the record of who was there. Next: NSGC 2027, Nov 7–11, 2027 in Tampa
Rare disease at NSGC 2026
Nov 10–14, 2026 Baltimore, MD ~2.5k attendees Website
42 organizations at NSGC 2026 present work in rare disease: 19 drug developers, 15 testing labs and software companies, 5 advocacy groups, foundations and societies, 2 research institutes and registries and 1 clinic or hospital. Between them they bring 15 presentations to the program. 42 of them have their own page in this guide. As of Nov 12, 2026.
| Organization | NSGC 2026 Attendance |
|---|---|
Ambry Genetics Aliso Viejo, CA | |
Clinical genetic testing laboratory, part of Tempus, offering hereditary cancer, rare disease and whole-genome testing with RNA analysis and automatic reanalysis. | Booth Exhibiting at Booth 1169 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Thu Nov 12 12:15–1:30pm Uncovering the Complete Picture: Transforming Rare Disease Care for Every Patient Shows how Ambry's clinical genome sequencing, RNA testing and automatic report reanalysis aim to raise diagnostic yield in rare disease. Hosts a sponsored reception for attendees, Thu Nov 12, 8–11pm |
Natera Austin, TX | |
Cell-free DNA testing laboratory offering prenatal screening (NIPT), carrier screening, oncology and transplant tests, and rare disease genetic testing. | Booth Exhibiting at Booth 1263 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Wed Nov 11 12:15–1:30pm Shifting the NIPT Paradigm: The Impact of Clinically Validated Accuracy at Low Fetal Fraction Presents validation data for Natera's updated Panorama prenatal screen at fetal fractions as low as 1%, and what it means for counseling. Symposium Thu Nov 12 7:45–8:30am Beyond the Report: Bridging the Gap Between Rare Disease Diagnosis and Clinical Trial Access Describes Natera's Zenith service, which matches patients' rare disease results to open clinical trials and alerts their clinicians. |
Acadia Pharmaceuticals San Diego, CA | |
Biopharmaceutical company with approved treatments for Rett syndrome and Parkinson's disease psychosis, developing further medicines for neurological and rare conditions. | Booth Exhibiting at Booth 963 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 7:45–8:30am Rett Syndrome Management Your Way: Two Formulations of the First and Only FDA-Approved Treatment Covers Rett syndrome care with both forms of Acadia's FDA-approved Rett treatment, DAYBUE and DAYBUE STIX. |
Alexion, AstraZeneca Rare Disease Boston, MA | |
AstraZeneca's rare disease company, with medicines for conditions including hypophosphatasia, lysosomal acid lipase deficiency, neurofibromatosis type 1 and complement disorders. | Booth Exhibiting at Booth 1155 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 12:15–1:30pm Recognize What Might Be Missed: Changing the Patient Journey in HPP, LAL-D, NF1 Reviews the clinical clues to hypophosphatasia, lysosomal acid lipase deficiency and neurofibromatosis type 1, to help clinicians recognize them earlier. |
Ascendis Pharma Copenhagen, Denmark | |
Biopharmaceutical company developing long-acting treatments for rare endocrine and skeletal conditions, including achondroplasia. | Booth Exhibiting at Booth 1055 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Wed Nov 11 7:45–8:30am Discover Yuviwel® (navepegritide) Introduces Ascendis' Yuviwel (navepegritide), covering how it works, its clinical trial results and how it is dosed. |
Baylor Genetics Houston, TX | |
Genetic testing laboratory, a joint venture with Baylor College of Medicine, offering genome, exome and panel testing from prenatal through adult care. | Booth Exhibiting at Booth 1376 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Wed Nov 11 12:15–1:30pm Reimagining Genomic Testing Across the Care Continuum (from Prenatal to Postnatal) Argues for genome-first prenatal testing and extra technologies beyond genome sequencing after birth, to find diagnoses that standard tests miss. |
BioMarin San Rafael, CA | |
Biotech company with medicines for rare genetic conditions, including achondroplasia and other skeletal disorders, PKU and several lysosomal storage disorders. | Booth Exhibiting at Booth 1150, 1243, 1342 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Thu Nov 12 7:45–8:30am Hypochondroplasia: Advancing Diagnosis and Genetic Counseling in an Evolving Clinical Landscape Follows patients with hypochondroplasia from first suspicion to genetic confirmation and counseling, including FGFR3 variant interpretation and emerging treatments. |
BridgeBio Palo Alto, CA | |
Biotech company developing medicines for genetic conditions, including transthyretin amyloid cardiomyopathy and achondroplasia. | Booth Exhibiting at Booth 1247, 1347 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 7:45–8:30am One Diagnosis, Many Conversations: The Evolving Landscape of Care in Achondroplasia and the Role of Genetic Counselors Traces achondroplasia care from prenatal recognition through childhood treatment choices to adult family planning, and the genetic counselor's role throughout. |
Exact Sciences Madison, WI | |
Genetic testing company, now part of Abbott, offering germline exome and panel testing through its PreventionGenetics lab plus a multi-cancer early detection blood test. | Booth Exhibiting at Booth 1069 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Wed Nov 11 7:45–8:30am Decoding Multi-Cancer Early Detection (MCED) Testing: The Science and Evidence Behind the Cancerguard® Test Explains how Exact Sciences' Cancerguard multi-cancer early detection test combines DNA methylation and protein markers, and how to read its evidence. |
Clinical genetic testing laboratory focused on exome and genome sequencing for rare disease diagnosis, drawing on a large rare disease dataset. | Booth Exhibiting at Booth 969 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Wed Nov 11 12:15–1:30pm CSI: Clinical Sequencing Investigation: Applying Genomic Evidence to Solve the Case An escape-room-style case where attendees use phenotype clues, variant evidence and AI prioritization tools to reach a genomic diagnosis. |
Lilly Indianapolis, IN | |
Global pharmaceutical company whose genetic medicine work includes gene therapy for hereditary hearing loss; sponsors a session on hearing loss genetic testing. | Booth Exhibiting at Booth 1363 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 7:45–8:30am Partners in Diagnosis: Collaborative Models for Genetic Testing and Counseling in Hereditary Hearing Loss Uses hereditary hearing loss to show how genetic counselors, audiologists and otolaryngologists can team up so genetic testing is routinely offered. |
Sanofi Paris, France | |
Global pharmaceutical company with rare disease medicines, including enzyme replacement therapies for Gaucher, Pompe and Fabry disease. | Booth Exhibiting at Booth 1148, 1165 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 12:15–1:30pm One Rare Disease, Three Perspectives: How Genetic Counselors Across Clinic, Research, and Industry Shape Patient Care Uses Gaucher disease type 3 to show how genetic counselors in clinics, research and industry each shape diagnosis and care. |
Online research registry gathering long-term data and samples from families with rare genetic neurodevelopmental disorders, shared with approved researchers. | Booth Exhibiting at Booth 1279 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 12:15–1:30pm The Longitudinal Journey: Supporting Families and Accelerating Research After Diagnosis Shows how genetic counselors can steer families into long-term research after a diagnosis, with the Simons Searchlight registry as the case study. |
Variantyx Framingham, MA | |
Genetic testing laboratory using whole genome sequencing for rare disorder diagnosis, reproductive genetics and precision oncology. | Booth Exhibiting at Booth 1269 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Thu Nov 12 7:45–8:30am Navigating the Genomic Era: Diagnostic Yield and Ethical Challenges Draws on over 100,000 genome sequencing cases to weigh diagnostic yield across ages and hard reporting calls like prenatal VUS. |
Clinical genetic testing laboratory for inherited and somatic conditions, from single genes and panels to exome, genome, long-read and RNA sequencing. | Booth Exhibiting at Booth 963 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Find buyers in rare disease
Tell us what you sell and we’ll find the people at organizations working on rare disease most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse NSGC 2026 by
Not affiliated with or endorsed by the National Society of Genetic Counselors (NSGC). Organization details are derived from NSGC’s published exhibitor list and program, and each organization’s own website. Submit a correction